The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Breast Cancer in Men
Abstract
PURPOSE: Breast cancer in men is uncommon; 1500 new cases are diagnosed in the United States yearly. Optimal management of breast cancer in men is unknown because the rarity of the disease precludes large randomized trials. A review of the literature was undertaken with emphasis on articles published over a 10-year period. DATA SOURCES: Articles published between 1942 and 2000 on breast cancer in men were identified by using CancerLit, MEDLINE, and study bibliographies. STUDY SELECTION: All retrospective series and studies focusing on the epidemiology, risk factors, genetics, and pathology of breast cancer in men. DATA EXTRACTION: Data on the epidemiology, risk factors, genetics, pathology, molecular markers, prognostic factors, therapy, and outcomes of breast cancer in men. DATA SYNTHESIS: Carcinoma of the male breast accounts for 0.8% of all breast cancers. Risk factors include testicular disease, benign breast conditions, age, Jewish ancestry, family history, and the Klinefelter syndrome. BRCA2 mutations predispose men to breast cancer and may account for 4% to 14% of all cases. Pathology data were reviewed: 81% of tumors were estrogen receptor positive, 74% were progesterone receptor positive, 37% overexpressed c-erbB-2, 30% overexpressed p53, 79% overexpressed Bcl-2, 51% overexpressed cyclin D1, and 39% overexpressed epidermal growth factor receptor. Prognostic factors include tumor size, histologic grade, and lymph node status; survival is similar to that of breast cancer in women when patients are matched for age and stage. Adjuvant hormonal therapy and chemotherapy, using the same guidelines as for women, are recommended for men. Hormonal therapy is the primary therapy for metastatic disease; chemotherapy should be reserved for hormone-refractory disease. CONCLUSION: Breast cancer is similar in men and women; however, breast cancer in men is more frequently hormone receptor positive and may be more sensitive to hormonal therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Jemal, A., Thomas, A., Murray, T., & Thun, M. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.1.23 · Cited by 2,917
Localization of a Breast Cancer Susceptibility Gene, BRCA2 , to Chromosome 13q12-13
Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Averill, D., et al. (1994) · Science · doi:10.1126/science.8091231 · Cited by 1,924
Thorlacius, S., Olafsdottir, G., Tryggvadottir, L., Neuhausen, S., Jonasson, J. G., Tavtigian, S. V., Tulinius, H., Ögmundsdottir, H. M., & Eyfjörd, J. E. (1996) · Nature Genetics · doi:10.1038/ng0596-117 · Cited by 525
Desforges, J. F., & Braunstein, G. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280708 · Cited by 402
Sasco, A. J., Lowenfels, A. B., & Jong, P. C. M. P.-D. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530403 · Cited by 397
Bcl-2 protein expression and long-term survival in breast cancer.
Joensuu, H., Pylkkänen, L. H., & Toikkanen, S. (1994) · PubMed · Cited by 396
BRCA2 germline mutations in male breast cancer cases and breast cancer families
Couch, F. J., Farid, L. M., DeShano, M. L., Tavtigian, S. V., Calzone, K., Campeau, L., Peng, Y., Bogden, B., Chen, Q., Neuhausen, S., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-123 · Cited by 363
Goss, P. E., Reid, C., Pintilie, M., Lim, R., & Miller, N. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990201)85:3<629::aid-cncr13>3.0.co;2-v · Cited by 325
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.
Friedman, L. S., Gayther, S. A., Kurosaki, T., Gordon, D., Noble, B., Casey, G., Ponder, B. A. J., & Anton‐Culver, H. (1997) · PubMed · Cited by 275
Cited by
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Self-citationEpidemiological characteristics of and risk factors for breast cancer in the world
Momenimovahed, Z., & Salehiniya, H. (2019) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s176070 · Cited by 1,050
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010173 · Cited by 845
Breast carcinoma in men: A population‐based study
Giordano, S. H., Cohen, D. S., Buzdar, A. U., Perkins, G., & Hortobagyi, G. N. (2004) · Cancer · doi:10.1002/cncr.20312 · Cited by 789
Self-citation
Metadata
- Authors
- Giordano, S. H., Buzdar, A. U., & Hortobagyi, G. N.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2002-10-15
- Volume
- 137
- Issue
- 8
- Pages
- 678-687
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1989151442
- Cited by
- 490
- References
- 59
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breast Cancer in Men. https://app.cochat.ai/papers/10.7326/0003-4819-137-8-200210150-00013
- The paper
- Giordano, S. H., Buzdar, A. U., & Hortobagyi, G. N. (2002). Breast Cancer in Men. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-137-8-200210150-00013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.